Work

Abstract CT154: BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct154

Authors: Ecaterina E. Dumbrava, Ildefonso Ismael Rodriguez, M. Adham Salkeni, Antonio Giordano, Chris Chen, Sheena Sahota, Edith A. Perez, Tai Yu, Katherine Rosenthal, Kristi Balacy, Danlin Cai, Jason Ptacek, Lu Xu, Dawn Colburn, Shelley E. Ackerman, Michael N. Alonso, Justin A. Kenkel, Andrae Vandross

Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Stanford Cancer Institute, Stanford University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821974

Cites:

Cited by: 1

Related to: 10